RIVAXO 15 MG TABLET

RIVAXO 15 MG TABLET contains Rivaroxaban as its active ingredient. It belongs to the class of direct factor Xa inhibitors and acts as an oral anticoagulant. Rivaroxaban works by inhibiting factor Xa, a key enzyme in the coagulation cascade, thereby preventing the formation of blood clots.

Mechanism of Action:

Rivaroxaban exerts its anticoagulant effect by selectively and reversibly inhibiting factor Xa. Factor Xa plays a crucial role in the coagulation process by catalyzing the conversion of prothrombin to thrombin. By blocking factor Xa, rivaroxaban prevents the formation of thrombin, inhibiting the subsequent conversion of fibrinogen to fibrin and reducing the risk of thrombus formation.

Uses:

RIVAXO 15 MG TABLET is indicated for various medical conditions where anticoagulation is required to prevent or treat blood clots. These include:

• Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery.
• Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
• Prevention of recurrent DVT and PE.

Dosage and Administration:

The dosage of RIVAXO 15 MG TABLET varies depending on the medical condition being treated and individual patient factors. It is typically taken orally once daily with or without food. It is essential to follow the prescribed dosage and administration instructions provided by the healthcare provider.

Side Effects:

Common side effects associated with RIVAXO 15 MG TABLET may include:

• Bleeding (including gastrointestinal bleeding)
• Bruising
• Hemorrhage
• Headache
• Dizziness
• Nausea
• Fatigue

Precautions:

• RIVAXO 15 MG TABLET should be used with caution in patients at an increased risk of bleeding, such as those with a history of gastrointestinal bleeding, bleeding disorders, or concomitant use of other anticoagulant medications.
• It is essential to monitor renal function regularly in patients with impaired renal function as rivaroxaban is primarily excreted via the kidneys.
• Patients should be advised to report any signs or symptoms of bleeding, such as unusual bruising, blood in the urine or stools, or prolonged bleeding from minor cuts or injuries, to their healthcare provider promptly.
• RIVAXO 15 MG TABLET should be used with caution in patients with hepatic impairment, as rivaroxaban metabolism may be affected.

Conclusion:

RIVAXO 15 MG TABLET, containing Rivaroxaban, is an oral anticoagulant used for the prevention and treatment of various thromboembolic disorders. By inhibiting factor Xa, rivaroxaban helps prevent the formation of blood clots and reduces the risk of thromboembolic events. However, it is essential to use this medication cautiously and under the guidance of a healthcare provider due to the risk of bleeding complications.